Background : Diabetes melitus was related to  the  risk of increased morbidity and mortality in patients that infected with SARS-CoV-2 virus.  The treatment of COVID-19 patients were carried out with different treatment time intervals for each person. This is caused by a decrease in immune function in diabetes mellitus patients and is one of the factors that worsen the situation of COVID-19 patients. Some studies have found significant correlation between HbA1c level and COVID-19 progression or mortality since HbA1c reflects the average glycaemia over the preceding 2 to 3 months, whereas others have not. Methods : This study used a cross-sectional method with retrospective analytics design to determine the correlation between HbA1c level and length of stay of diabetes mellitus patient who are treated with COVID-19. This study used medical record files as the research instruments. Results : The results of this study indicate that the patients gender are equal between male and female. The majority of patients age are in the range of 41 – 60 years old. The majority of patients HbA1c level are 6,5%. The majority of patients blood glucose level are >180 mg/dL. The majority of patients length of stay are more than 21 days. The results of the multiple linear regression test showed that there is no correlation between the HbA1c level and the length of stay. Conclusion : This study shows that HbA1c is not related to the length of stay for patients  with diabetes mellitus who are hospitalized with COVID-19.

COVID-19

Diabetes Mellitus

length of stay

hba1c